AZNAstraZenecaRunning, no new patients
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 510 (final count)
- Started
- Sep 25, 2013
- Main results expected
- Jun 7, 2016
- Fully finished
- Dec 31, 2026
- Results posted
- Aug 29, 2017
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["statusModule"]}
Trial ID NCT01933932 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC